Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis.
Neuroplasticity and functional recovery in multiple sclerosis.
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial.
Remyelination Therapy for Multiple Sclerosis.
The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.
Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis.
Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential.
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients.
Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis.
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis.
Robust Perfusion Deficits in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis.
The role of the immune system in the generation of neuropathic pain.
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.
Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
Genetic control of nerve conduction velocity may influence multiple sclerosis phenotype.
A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation.
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).
On the Epidemiology of Multiple Sclerosis in the Middle East and North Africa.
The history of neuromyelitis optica.
[The role of dopamine in the regulation of the interaction between nervous and immune systems in multiple sclerosis.]
Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis.

Pages